Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,758.80
(
-1.55%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,318.24
(
-3.55%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tinkershaw post# 65739

Monday, 09/01/2008 6:50:09 PM

Monday, September 01, 2008 6:50:09 PM

Post# of 257257
There’s no question that the FDA considers potential off-label use of a drug in the thinking that goes into crafting a clinical-development program. How much of a factor this has been with Telaprevir is hard to say, but I’m sure it hasn’t been overlooked. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today